38 Discovery – Suite 150
92618 Irvine - USA Site web

Key figures

Creation date: 2001
Number of employees: 15
Investment date: 06/01/2017
Fund name: Mérieux Participations 2

Company presentation

Ivantis has developed the Hydrus™ Microstent, the world’s first “intracanalicular scaffold” for the treatment of primary open angle glaucoma (POAG). The Hydrus procedure is designed to be less invasive than traditional glaucoma surgery and can be performed during cataract surgery using the same microsurgical incisions. Roughly the size of an eyelash, the Hydrus Microstent is made from a super-elastic, biocompatible alloy (nitinol®), which is a well-proven biomaterial used in over 1 million implants in a variety of medical devices to date.

Produit et service